HUP0400030A3 - Antibodies specific for cd44v6 - Google Patents

Antibodies specific for cd44v6

Info

Publication number
HUP0400030A3
HUP0400030A3 HU0400030A HUP0400030A HUP0400030A3 HU P0400030 A3 HUP0400030 A3 HU P0400030A3 HU 0400030 A HU0400030 A HU 0400030A HU P0400030 A HUP0400030 A HU P0400030A HU P0400030 A3 HUP0400030 A3 HU P0400030A3
Authority
HU
Hungary
Prior art keywords
cd44v6
antibodies specific
antibodies
specific
Prior art date
Application number
HU0400030A
Other languages
English (en)
Hungarian (hu)
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of HUP0400030A2 publication Critical patent/HUP0400030A2/hu
Publication of HUP0400030A3 publication Critical patent/HUP0400030A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2884—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD44
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
HU0400030A 2001-05-18 2002-05-17 Antibodies specific for cd44v6 HUP0400030A3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP01112237 2001-05-18
US32514701P 2001-09-26 2001-09-26
PCT/EP2002/005467 WO2002094879A1 (en) 2001-05-18 2002-05-17 Antibodies specific for cd44v6

Publications (2)

Publication Number Publication Date
HUP0400030A2 HUP0400030A2 (hu) 2004-04-28
HUP0400030A3 true HUP0400030A3 (en) 2006-02-28

Family

ID=33442672

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0400030A HUP0400030A3 (en) 2001-05-18 2002-05-17 Antibodies specific for cd44v6

Country Status (18)

Country Link
EP (1) EP1397387A1 (enExample)
JP (1) JP2005504517A (enExample)
CN (1) CN1541226A (enExample)
AR (1) AR036154A1 (enExample)
BR (1) BR0210905A (enExample)
CA (1) CA2443437A1 (enExample)
CZ (1) CZ20033476A3 (enExample)
EA (1) EA200301169A1 (enExample)
EC (1) ECSP034838A (enExample)
EE (1) EE200300569A (enExample)
HU (1) HUP0400030A3 (enExample)
MX (1) MXPA03010523A (enExample)
PE (1) PE20021098A1 (enExample)
PL (1) PL365735A1 (enExample)
SK (1) SK15592003A3 (enExample)
WO (1) WO2002094879A1 (enExample)
YU (1) YU91403A (enExample)
ZA (1) ZA200307365B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050100542A1 (en) 1999-10-08 2005-05-12 Young David S. Cytotoxicity mediation of cells evidencing surface expression of CD44
US8071072B2 (en) 1999-10-08 2011-12-06 Hoffmann-La Roche Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US7947496B2 (en) 1999-10-08 2011-05-24 Hoffmann-La Roche Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US8048416B2 (en) 1999-10-08 2011-11-01 Hoffmann-La Roche Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US7189397B2 (en) 1999-10-08 2007-03-13 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US7084257B2 (en) 2001-10-05 2006-08-01 Amgen Inc. Fully human antibody Fab fragments with human interferon-gamma neutralizing activity
AU2005214331B2 (en) 2004-02-12 2011-09-15 Eisai, Inc. Monoclonal antibodies that specifically bind to folate receptor alpha
ES2429340T3 (es) 2005-03-10 2013-11-14 Morphotek, Inc. Anticuerpos anti-mesotelina
AU2006241099B2 (en) 2005-04-22 2012-04-19 Eisai, Inc. Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cells
DK2167038T3 (en) * 2007-06-13 2018-08-06 Zymogenetics Inc USING TACI-IG FUSION PROTEIN AS ATACICEPT TO PREPARE A MEDICINE FOR TREATING LUPUS ERYTHEMATOSUS
EP2009028A1 (en) * 2007-06-27 2008-12-31 Monoclonal Antibodies Therapeutics Combination of a conventional anti-cancer treatment with anti-CD44 antibody administration for treating solid tumors
AU2011212485B2 (en) 2010-02-04 2014-04-17 University Of Miami A monoclonal antibody to CD44 for use in the treatment of head and neck squamous cell carcinoma
CN102337298B (zh) * 2011-08-19 2013-11-06 黄开红 一种输送siRNA的免疫纳米载体及其制备方法和应用
US20140335084A1 (en) 2011-12-06 2014-11-13 Hoffmann-La Roche Inc. Antibody formulation
WO2017215637A1 (zh) * 2016-06-15 2017-12-21 李翀 一种人子宫内膜癌的标志物、抗体及其应用
CN107556388A (zh) * 2016-06-30 2018-01-09 中国科学院深圳先进技术研究院 抗CD44v6和CD3特异性双靶向抗体、含该双靶向抗体表达盒的微环DNA及应用
JP2023516080A (ja) * 2020-03-06 2023-04-17 ジーオー セラピューティクス，インコーポレイテッド 抗グリコｃｄ４４抗体およびその使用
US20250326855A1 (en) * 2021-03-05 2025-10-23 Go Therapeutics, Inc. Anti-glyco-cd44 antibodies and their uses

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL162181A (en) * 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP0438310A1 (en) * 1990-01-19 1991-07-24 Merck & Co. Inc. Method for producing recombinant immunoglobuline
GB9020282D0 (en) * 1990-09-17 1990-10-31 Gorman Scott D Altered antibodies and their preparation
WO1994012631A1 (en) * 1992-11-20 1994-06-09 Isis Innovation Limited Peptide corresponding to cd44 exon 6, antibodies specific for said peptide and use of these antibodies for diagnosis of tumors
UA58482C2 (uk) * 1994-06-08 2003-08-15 Бьорінгер Інгельхайм Інтернаціональ Гмбх Моноклональне антитіло vff-18 проти сd44v6 і його фрагменти
UY24389A1 (es) * 1995-12-06 2001-10-25 Karlsruhe Forschzent Composición farmacéutica para el tratamiento de carcinoma de epitelio plano

Also Published As

Publication number Publication date
EA200301169A1 (ru) 2004-06-24
CN1541226A (zh) 2004-10-27
PE20021098A1 (es) 2003-02-11
EE200300569A (et) 2004-04-15
CZ20033476A3 (cs) 2004-05-12
YU91403A (sh) 2006-05-25
AR036154A1 (es) 2004-08-18
EP1397387A1 (en) 2004-03-17
WO2002094879A1 (en) 2002-11-28
MXPA03010523A (es) 2004-07-01
ECSP034838A (es) 2003-12-24
ZA200307365B (en) 2004-05-10
CA2443437A1 (en) 2002-11-28
PL365735A1 (en) 2005-01-10
BR0210905A (pt) 2004-06-08
HUP0400030A2 (hu) 2004-04-28
SK15592003A3 (sk) 2004-06-08
JP2005504517A (ja) 2005-02-17

Similar Documents

Publication Publication Date Title
EP1432444A4 (en) ANTI-BETA ANTIBODIES
EP1467756A4 (en) METHODS OF USING ANTI-MUC18 ANTIBODIES
EP1494693A4 (en) SPECIFIC ANTIBODIES TO CRIPTO
PL375405A1 (en) Antibodies
AU2002256895A1 (en) Anti-TRAIL-R antibodies
EP1616881A4 (en) ANTI-MPL ANTIBODIES
PT1599504E (pt) Anticorpo modificado
IL175608A0 (en) Antibodies
AU2002365649A8 (en) Anti-dota antibody
HUP0400030A3 (en) Antibodies specific for cd44v6
EP1437410A4 (en) NEW SELENOCYSTEIN CONTAINING PROTEINS
IL163580A0 (en) Assay for anti-ingap antibodies
GB0226878D0 (en) Antibodies
GB0105402D0 (en) Novel proteins
IL157966A0 (en) Antibodies specific for cd44v6
GB0031284D0 (en) High affinity antibodies
GB0118696D0 (en) Novel antibodies
GB0119553D0 (en) Antibodies
GB0217742D0 (en) Novel antibodies
GB0105401D0 (en) Novel proteins
GB0100750D0 (en) Novel proteins
GB0120494D0 (en) Novel antibody
GB0218235D0 (en) Antibodies
GB0218229D0 (en) Antibodies
GB0218230D0 (en) Antibodies

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees